Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: A multicenter, randomized clinical trial by Durante Mangoni, Emanuele et al.
M A J O R A R T I C L E
Colistin and Rifampicin Compared With Colistin
Alone for the Treatment of Serious Infections
Due to Extensively Drug-Resistant Acinetobacter
baumannii: A Multicenter, Randomized Clinical
Trial
Emanuele Durante-Mangoni,1 Giuseppe Signoriello,2 Roberto Andini,1 Annunziata Mattei,3 Maria De Cristoforo,4
Patrizia Murino,3 Matteo Bassetti,5,a Paolo Malacarne,6 Nicola Petrosillo,7 Nicola Galdieri,3 Paola Mocavero,3
Antonio Corcione,3 Claudio Viscoli,5 Raffaele Zarrilli,8 Ciro Gallo,2 and Riccardo Utili1
1Internal Medicine Section, Department of Cardiothoracic Sciences, University of Naples S.U.N. and AORN Ospedali dei Colli, Monaldi Hospital,
2Medical Statistics, Department of Medicine and Public Health, University of Naples S.U.N.; 3Anesthesia and Intensive Care Unit, AORN Ospedali dei
Colli, Monaldi Hospital, and 4Anesthesia and Intensive Care Unit, AORN Cardarelli, Naples; 5Infectious Diseases Division, San Martino University
Hospital and University of Genoa; 6Intensive Care Unit, Emergency Department, AOU Pisana, Pisa; 7Second Infectious Diseases Division, National
Institute for Infectious Diseases ‘L. Spallanzani,’ Rome; and 8Department of Public Health, University of Naples Federico II, Naples, Italy
(See the Editorial Commentary by Gauthier on pages 359–61.)
Background. Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in criti-
cally ill patients. Colistin often remains the only therapeutic option. Addition of rifampicin to colistin may be syner-
gistic in vitro. In this study, we assessed whether the combination of colistin and rifampicin reduced the mortality of
XDR A. baumannii infections compared to colistin alone.
Methods. This multicenter, parallel, randomized, open-label clinical trial enrolled 210 patients with life-threat-
ening infections due to XDR A. baumannii from intensive care units of 5 tertiary care hospitals. Patients were ran-
domly allocated (1:1) to either colistin alone, 2 MU every 8 hours intravenously, or colistin (as above), plus
rifampicin 600 mg every 12 hours intravenously. The primary end point was overall 30-day mortality. Secondary
end points were infection-related death, microbiologic eradication, and hospitalization length.
Results. Death within 30 days from randomization occurred in 90 (43%) subjects, without difference between
treatment arms (P = .95). This was conﬁrmed by multivariable analysis (odds ratio, 0.88 [95% conﬁdence interval,
.46–1.69], P = .71). A signiﬁcant increase of microbiologic eradication rate was observed in the colistin plus rifampi-
cin arm (P = .034). No difference was observed for infection-related death and length of hospitalization.
Conclusions. In serious XDR A. baumannii infections, 30-day mortality is not reduced by addition of rifampicin
to colistin. These results indicate that, at present, rifampicin should not be routinely combined with colistin in clinical
practice. The increased rate of A. baumannii eradication with combination treatment could still imply a clinical beneﬁt.
Clinical Trials Registration. NCT01577862.
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Extensively drug-resistant (XDR) Acinetobacter bau-
mannii (Acb) [1] is increasingly recognized as an
etiologic agent of nosocomial infections associated with
high mortality in critically ill patients [2–5].
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Epidemic XDR isolates of Acb may show resistance to almost
all classes of antimicrobials, including carbapenems [4, 6, 7]. In
these infections, the only viable therapeutic option may be repre-
sented by colistin [8–11], despite its relatively low intrinsic efﬁ-
cacy, a suboptimal lung penetration, and the risk for signiﬁcant
renal toxicity [6, 12–15]. However, even with colistin treatment,
mortality remains high [16].
Synergy against XDR Acb was shown in both in vitro [17–19]
and experimental studies [20, 21] when colistin was combined
with rifampicin, prompting their combined clinical use in XDR
Acb infections. Three uncontrolled clinical studies have assessed
the safety and clinical efﬁcacy of the colistin-rifampicin combi-
nation, showing very high overall response rates, without major
adverse events [22–24]. By altering membrane permeability, co-
listin may facilitate rifampicin entry within the bacterial cell and
therefore enhance its killing activity [25, 26]. However, no proof
of superiority of the colistin-rifampicin combination over colis-
tin monotherapy was provided.
Therefore, we performed a randomized controlled trial to
assess whether the addition of rifampicin to colistin reduced
the mortality of patients with life-threatening infections due to
XDR Acb compared to colistin alone.
METHODS
Study Design
This was a multicenter, open-label, parallel, phase III, random-
ized clinical trial. Patients were randomly allocated to either co-
listin (control arm) or colistin plus rifampicin (experimental
arm) on a 1:1 basis. The study was conducted in accordance
with the ethical principles of the Declaration of Helsinki and of
Good Clinical Practice. The ethics committee of each partici-
pating institution approved the study. The study was designed
by the academic investigators and was approved, endorsed, and
funded by the Italian Medicines Agency. All patients provided
written informed consent. In case of patient unconsciousness, the
informed consent was obtained by his/her legal representative.
Participants
Enrolled patients were hospitalized in the intensive care units
(ICUs) of 5 large Italian clinical centers. Subjects were catego-
rized as having been admitted initially to the ICU or transferred
to the ICU from medical or surgical wards. Adult subjects (>18
years) were eligible for the study if they had microbiologic evi-
dence of a life-threatening nosocomial infection due to XDR
Acb [1] susceptible to colistin (minimum inhibitory concentra-
tion [MIC], ≤2 mg/L). Infections included hospital-acquired
pneumonia (HAP), ventilator-associated pneumonia (VAP),
bloodstream infection (BSI), and complicated intra-abdominal
infection (cIAI). Severity of the underlying illnesses was assessed
by the Simpliﬁed Acute Physiology Score (SAPS) II [27]. Co-
morbidities were assessed by the Charlson index [28].
Exclusion criteria were previous treatment with colistin or rifam-
picin during the index hospitalization, reported hypersensitivity to
either study drug, or signiﬁcant liver dysfunction (deﬁned by
serum conjugated bilirubin >3 mg/dL). Enrollment was done
irrespective of the strain MIC of rifampicin, as this is not rou-
tinely tested in clinical microbiology practice. Rifampicin
MICs were tested subsequently for all baseline and follow-up
strains in a centralized laboratory, and results were included in
the multivariable analysis of treatment outcome.
Deﬁnitions
“Extensively drug resistant” was deﬁned as resistance to carba-
penems (MIC ≥16 mg/L) and to all other antimicrobial drug
classes, except colistin [1]. HAP/VAP was diagnosed as an
evolving inﬁltrate on chest radiograph with either fever or leu-
kocytosis/leukopenia or purulent respiratory secretions with
positive quantitative culture from tracheal aspirate (at least 106
colony-forming units [CFU]/mL) or bronchoalveolar lavage (at
least 104 CFU/mL) [29]. BSI was deﬁned as positive blood cul-
tures for Acb in the presence of systemic inﬂammatory signs [30].
Complicated intra-abdominal infections were diagnosed as a
positive Acb culture of purulent exudate from abdominal col-
lections, associated with a systemic inﬂammation [31].
Infection-related death was deﬁned as death occurring in the
presence of persistent clinical signs and microbiologic evidence
of Acb infection (persistent pneumonia, abdominal discharge,
septic shock, persistently positive cultures, raised inﬂammatory
markers). Microbiologic eradication was deﬁned as disappear-
ance of Acb in all follow-up cultures from the primary source
of infection (ie, blood, bronchoalveolar lavage, or bronchial as-
pirate, drainage ﬂuids) during treatment.
Clinical cure was deﬁned as disappearance of symptoms and
signs of infection, irrespective of Acb eradication at the site of in-
fection. Therapeutic failure was deﬁned as worsening at any time
or no improvement of clinical conditions by day 21 of therapy in
the presence of persistently positive Acb cultures. Renal toxicity
was deﬁned according to the RIFLE (risk, injury, failure, loss,
end-stage renal disease) criteria [32, 33] in terms of changes of
serum creatinine levels relative to baseline. Hepatic toxicity was
deﬁned as an increase of conjugated bilirubin >3 mg/dL.
Interventions
The control arm received colistin alone, available in Italy as col-
istimethate sodium (Colimicina, UCB Pharma SpA, Milan,
Italy), at an initial dose of 2 million units (equal to 160 mg of
colistimethate sodium) every 8 hours intravenously or accord-
ing to renal function (Supplementary Table 1). In addition to
colistin, at the same dose, the experimental arm received ri-
fampicin, 600 mg every 12 hours intravenously. Treatment
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assignment was not blinded because of the pragmatic nature of
the study. Treatment had to be administered for at least 10 days
and up to a maximum of 21 days. Length of treatment was de-
termined by the physician in charge. Drug dosages were adjust-
ed based on actual renal and liver function according to a
predeﬁned protocol (Supplementary Table 1) [9–12].
Treatment was discontinued in case of clinical cure (with or
without microbiologic eradication), therapeutic failure, occur-
rence of severe renal or liver toxicity, or patient death. Coinfec-
tions were treated by the physician in charge according to
current guidelines [29–31]. Except for rifampicin in the control
group, any other drug was allowed, where needed. Aerosolized
colistin was not allowed in any of the 2 treatment arms and no
patient received it at any time during the study. Retrieval of
clinical, laboratory, and microbiologic data, including concomi-
tant or superimposed pathogens, was performed at days 1, 4, 7,
11, 14, 21, and 30 after randomization.
All isolates were originally identiﬁed as A.baumannii–
Acinetobacter calcoaceticus complex using the VITEK 2 system
(bioMérieux, Marcy l’Étoile, France). Species identiﬁcation was
conﬁrmed by ampliﬁcation of the blaOXA−51−like gene and by a
trilocus sequencing typing protocol speciﬁc for Acb [34]. All
strains prospectively isolated underwent routine antimicrobial
susceptibility testing, including determination of colistin MIC.
Subsequently, all strains were sent to the coordinating center
reference laboratory and stored for further use. Rifampicin sus-
ceptibility was determined in this laboratory by the microdilu-
tion method in Mueller–Hinton broth II according to Clinical
and Laboratory Standards Institute guidelines [35]. In the
absence of internationally recognized breakpoints, Acb resis-
tance to rifampicin was deﬁned as an MIC >16 mg/L according
to the recommendations of the French Society of Microbiolo-
gy [36] and our previous studies [37].
Outcomes
The primary study outcome was 30-day mortality, deﬁned as
death for any cause occurring within 30 days from randomiza-
tion. Length of follow-up was at least 30 days from randomiza-
tion in all patients. Follow-up was extended to the end of the
hospitalization when this occurred later than 30 days.
Figure 1. Study ﬂow according to CONSORT statement.
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Secondary efﬁcacy outcomes were infection-related death,
microbiologic eradication, hospitalization length, and emer-
gence of resistance to colistin during treatment. Because of the
study setting (ICU) and the severity of patient conditions, the
toxicity assessment was limited to the following adverse events:
renal dysfunction and neurotoxicity, possibly related to colistin;
and hepatic dysfunction, possibly related to rifampicin.
Sample Size
The study was designed to identify an absolute mortality reduc-
tion of 20%. Assuming a raw 30-day mortality rate of 60% in
the control group [16, 37], a 2-tailed signiﬁcance level of .05, a
power of 0.8, an allocation ratio of 1:1, and a drop-out rate of
10%, 207 patients had to be enrolled (East software version 4).
Randomization
Treatment was centrally assigned by the coordinating center
(Naples University) according to a randomization list prepared
in advance by the Medical Statistics Unit, stratiﬁed by center
and SAPS II score (≤40, >40). Random sequence was generated
using random permuted blocks of unequal length. Randomiza-
tion was performed as soon as Acb was isolated, avoiding
delays in active treatment initiation.
Statistical Methods
Efﬁcacy analyses were based on an intention-to-treat strategy.
Dichotomous outcomes were compared by χ2 test, using exact
procedures. Odds ratios (ORs), with 95% conﬁdence intervals
(CIs), were estimated by a logistic regression model with
Table 1. Baseline Characteristics of the Study Patients
Characteristic All Patients (n = 209) Colistin + Rifampicin Arm (n = 104) Colistin Arm (n = 105)
Age, y, mean (SD) 62 (15.4) 62 (15.1) 61 (15.7)
Male sex 137 (65.6%) 67 (64.4%) 70 (66.7%)
SAPS II score, mean (SD) 39.9 (11.0) 40.8 (10.8) 39.0 (11.1)
Primary diagnosis
Ventilator-associated pneumonia 144 (69.8%) 71 (68.3%) 73 (69.5%)
Bloodstream infection 42 (20.1%) 21 (20.2%) 21 (20.0%)
Hospital-acquired pneumonia 18 ( 8.6%) 10 (9.6%) 8 (7.6%)
Complicated intra-abdominal infection 5 (2.4%) 2 (1.9%) 3 (2.9%)
Type of admission
Medical 42 (20.1%) 20 (19.2%) 22 (21.0%)
Surgical 40 (19.1%) 22 (21.2%) 18 (17.1%)
Emergency/ICU 127 (60.8%) 62 (59.6%) 65 (61.9%)
Comorbidities
None 29 (13.9%) 14 (13.5%) 15 (14.3%)
Congestive heart failure 48 (23.0%) 22 (21.2%) 26 (24.8%)
Chronic kidney disease 104 (49.8%) 51 (49.0%) 53 (50.5%)
Undergoing dialysis 36 (17.2%) 17 (16.3%) 19 (18.1%)
Diabetes mellitus 49 (23.4%) 22 (21.2%) 27 (25.7%)
Ischemic heart disease 56 (27.7%) 28 (27.7%) 28 (27.7%)
Chronic obstructive pulmonary disease 57 (27.3%) 29 (27.9%) 28 (26.7%)
Cerebrovascular disease/dementia 35 (16.7%) 18 (17.3%) 17 (16.2%)
Obesity (BMI >30 kg/m2) 41 (19.6%) 20 (19.2%) 21 (20.0%)
Malignancy 22 (10.5%) 11 (10.5%) 11 (10.4%)
Comorbidity index (Charlson)
0 36 (17.2%) 18 (17.3%) 18 (17.1%)
1 46 (22.1%) 22 (21.2%) 24 (22.9%)
2 58 (27.7%) 31 (29.8%) 27 (25.7%)
≥3 69 (33.0%) 33 (31.7%) 36 (34.3%)
Rifampicin MIC of first Acb isolate
≤16 160 (76.2%) 78 (75.0%) 82 (78.1%)
>16 43 (20.5%) 23 (22.1%) 20 (19.0%)
Missing 6 (2.9%) 3 (2.9%) 3 (2.8%)
Data are reported as No. (%), unless otherwise specified.
Abbreviations: Acb, Acinetobacter baumannii; BMI, body mass index; ICU, intensive care unit; MIC, minimum inhibitory concentration; SAPS, Simplified Acute
Physiology Score; SD, standard deviation.
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demographic (age and sex) and clinical (source of infection,
admission type, concomitant infections, SAPS II score, MIC
for rifampicin, comorbidity score) variables as covariates. Interac-
tion between treatment and MIC for rifampicin was also tested.
Length of hospitalization was described by reverse Kaplan-Meier
curves censoring dead subjects at the time of death [38].
Possible changes of treatment effect among categories of de-
mographic and clinical variables were assessed by Breslow-Day
test for homogeneity of odds ratios and depicted as Forest plot.
Statistical analyses were performed with Cytel Studio software
version 9.0.0 (Cytel Inc).
RESULTS
Patients
Two hundred ten subjects were randomized from 7 November
2008 to 29 July 2011 (Figure 1). One patient did not receive the
assigned treatment after randomization and was excluded from
all analyses. Seven patients (3 in the experimental arm and 4 in
the control arm) lacked complete treatment data because of
transfer to other hospitals or long-term care facilities or discharge
to home, but were included in the intention-to-treat analyses of
the primary outcome as 30-day survival data were obtained.
Main baseline characteristics of the study patients are sum-
marized in Table 1. No imbalances were observed between
treatment arms. The most frequent type of infection was VAP.
The majority of patients had been initially admitted to the hos-
pital in an ICU. The median treatment duration was 12.5 days
(interquartile range [IQR], 8–17 days). Discontinuation of
treatment was mainly due to patient death (Figure 1).
Clinical Outcomes
Efﬁcacy results are reported in Table 2. Death within 30 days
from randomization occurred in 90 (43%) subjects (61 during
treatment and 29 during follow-up), without any difference
between treatment arms (P = .95). The lack of difference between
the 2 arms was conﬁrmed by multivariate analysis (Table 3),
with an overall OR of treatment equal to 0.88 (95% CI, .46–1.69,
P = .71). Type of admission (P = .02), SAPS II score (P < .001),
and comorbidity score (P = .005) were signiﬁcantly associated
with 30-day mortality. Mortality was 45.2% in obese and 43.1%
in nonobese patients. Odds ratios and 95% CIs for treatment
effect are depicted in Figure 2 for patients grouped according to
categories of predeﬁned potentially predictive variables. No sig-
niﬁcant heterogeneity of treatment effect on the primary
outcome was observed for sex, age, primary diagnosis of infec-
tion, admission type, SAPS II score, Charlson comorbidity index,
Table 3. Logistic Regression Analysis of Variables Related to
Overall 30-Day Mortality
Parameter Odds Ratio 95% CI P Value
Treatment .71
Col + Rif vs Colistin 0.88 .46–1.69
Age, y .37
61–70 vs ≤60 1.47 .64–3.37
≥70 vs ≤60 1.82 .78–4.22
Sex .09
Female vs male 1.82 .92–3.65
Primary diagnosis .54
BSI vs VAP 2.02 .62–6.66
cIAI vs VAP 0.79 .10–6.18
HAP vs VAP 0.76 .33–1.74
Admission type .02
Medical vs emergency/ICU 2.25 .97 – 5.21
Surgical vs emergency/ICU 3.00 1.24–7.25
SAPS II score <.001
>40 vs ≤40 3.38 1.73–6.58
Comorbidity score (Charlson index) .008
CI 2–3 vs CI 0–1 1.42 .67–3.01
CI >3 vs CI 0–1 5.75 1.86–17.77
Coinfection 0.86 .44–1.69 .66
Rifampicin MIC .39
>16 vs ≤16 1.43 .63–3.20
Abbreviations: BSI, bloodstream infection; CI, confidence interval; cIAI, compli-
cated intra-abdominal infection; Col + Rif, colistin plus rifampicin; HAP, hospi-
tal-acquired pneumonia; ICU, intensive care unit; MIC, minimum inhibitory
concentration; SAPS, Simplified Acute Physiology Score; VAP, ventilator-
associated pneumonia.
Table 2. Efﬁcacy Outcomes
Outcome
Colistin + Rifampicin
Arm (n = 104)
Colistin Arm
(n = 105)
P
Value
Primary outcome
30-d mortality
Yes 45 (43.3%) 45 (42.9%) .95a
No 59 (56.7%) 60 (57.1%)
Secondary outcomes
Infection-related death at 30 d
Yes 22 (21.15%) 28 (26.6%) .29a
No 23 (22.1%) 17 (16.2%)
Acinetobacter baumannii eradication
Yes 63 (60.6%) 47 (44.8%) .034a
No 38 (36.5%) 54 (51.4%)
Median
hospitalization
length, d (IQR)
41 (26–61) 44 (27–59) .96b
Development of
colistin
resistance, %
0 0 . . .
Data are reported as No. (%) unless otherwise specified.
Abbreviation: IQR, interquartile range.
a Exact χ2 test.
b Log-rank test.
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presence of coinfections, and MIC of rifampicin (Figure 2). In
particular, no signiﬁcant interaction between treatment arm and
MIC of rifampicin (≤16 vs >16) was detected (P = .63). When pa-
tients infected with strains showing an MIC of rifampicin >16
were excluded, 30-day mortality rates in the remaining 160 pa-
tients were 46.2% in the combination arm and 43.9% in the colis-
tin arm (OR, 1.09; 95% CI, .59–2.04).
Mortality rates in the combination arm and in the control
arm were 61.2% and 61.7% respectively, in patients with SAPS
II score >40 and 57.1% and 50.8%, respectively, in patients with
a Charlson index score >2. In patients with an initial admission
in an ICU, death rates were 35.5% and 30.8% in the 2 treatment
arms, respectively.
When secondary outcomes were analyzed (Table 2), no dif-
ference was observed in terms of infection-related death and
length of hospitalization. In contrast, a signiﬁcant increase of
microbiologic eradication rate was observed in the colistin plus
rifampicin arm (P = .034). For 7 patients lost to follow-up no
information on secondary outcomes was available.
Kaplan-Meier curves of hospitalization length are reported
in Figure 3. Median length of hospitalization was equal to 41
days (IQR, 26–61 days) in the experimental arm and 44 days
(IQR, 27–59 days) in the control arm.
Colistin MIC was ≤0.5 mg/mL for all Acb isolates at ran-
domization. Resistance to colistin never occurred in any en-
rolled patient during treatment or follow-up. In contrast, 7
patients randomized to the experimental treatment developed
new onset resistance to rifampicin. Of them, 6 (86%) died.
Safety
A summary of toxicities observed in each treatment arm is pre-
sented in Table 4. Adverse events were observed in 70 (34.6%)
Figure 2. Subgroup analysis of 30-day mortality (Forest plot). The area of each square is proportional to the size of the subgroup; horizontal lines depict
95% conﬁdence intervals of the odds ratio estimates. Abbreviations: ICU, intensive care unit; MIC, minimum inhibitory concentration; OR, odds ratio;
SAPS, Simpliﬁed Acute Physiology Score; VAP, ventilator-associated pneumonia.
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patients, without differences between experimental and control
arm (35.7% and 33.7%, respectively). The most common
adverse event was renal impairment, which occurred in 53 pa-
tients (26.2%) and led to colistin dose reduction or discontinu-
ation in 17% of patients overall. In 2 subjects (1%), a worsening
of renal function leading to renal replacement therapy was re-
corded. The degree of renal toxicity according to the RIFLE cri-
teria is shown in Table 4. Despite receiving the same initial dose
of colistin, underweight patients (body mass index < 18) did not
show an increased rate of renal toxicity (3 of 15 [20%]). Liver
dysfunction associated with hyperbilirubinemia was more fre-
quent, though not signiﬁcantly, in the experimental arm, leading
to rifampicin dose reduction (9%) or discontinuation (48%)
(Table 4). No death was related to the study drug administration.
Coinfections
Concomitant microbial pathogens were isolated in 61% of
patients, without differences between treatment arms. Most
common copathogens were coagulase-negative staphylococci
and Pseudomonas aeruginosa. Consistently, concomitant anti-
microbial drugs were administered in 145 subjects (69.4%),
without differences between treatment arms (67.3% in the ex-
perimental arm and 71.4% in the control arm). Appropriate
therapy for any concomitant pathogen was administered in all
cases. Meropenem was employed in the control arm more fre-
quently than in the experimental arm (15.9% vs 3.9%), whereas
the reverse occurred with tigecycline (4.9% in the control arm
vs 10.9% in the experimental arm). These differences were not
statistically signiﬁcant. Details of the other microbial pathogens
isolated and the concomitant antimicrobial agents adminis-
tered are presented in Supplementary Table 2.
DISCUSSION
There is a strong need for randomized controlled trials for the
treatment of critically ill patients with infections due to Acb
and other nosocomial XDR pathogens [39]. This is the ﬁrst
study evaluating in a randomized fashion the efﬁcacy of colistin
and rifampicin combination compared with colistin alone in the
treatment of serious infections due to XDR Acb. Our results
indicate that 30-day mortality is not reduced by addition of ri-
fampicin to colistin. Moreover, combination treatment affected
neither infection-related death nor length of hospitalization.
Interestingly, however, Acb eradication from the primary source
of infection was more frequently observed with combination
treatment, consistent with previous experimental ﬁndings [17–
21]. Thus, a potentially beneﬁcial effect of combination treatment
Figure 3. Probability of discharge from hospital by treatment arm (Kaplan-Meier curve).
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could be disguised by the inherent complexity of enrolled patients
and the severity of their underlying illnesses. Indeed, as previous-
ly observed, 30-day mortality was high, irrespective of the treat-
ment received, and was associated with SAPS II score and
comorbid conditions, that is, the overall patient clinical status.
Consistently, mortality was higher in patients initially admitted
in wards other than the ICU, more often affected by chronic
medical comorbidities or undergoing surgery for cancer.
The dose of colistin used in this study (2 million units every
8 hours) was chosen based on existing recommendations at the
time the study protocol was approved [6, 9–12]. However, the
current trend is to use a high loading dose followed by 9
million units per day in 2–3 doses [13, 40, 41]. This regimen is
based on novel pharmacokinetic data [42] but is not supported
by any randomized trial. In this respect, the potential nephro-
toxicity of high-dose colistin is a major concern [13, 43], thus
its optimal dosing remains unknown. Of note, using up to 6
million units/day, we observed in this study signiﬁcant renal
toxicity in about 26% of patients, a ﬁnding that is consistent
with several previous observations showing that colistin neph-
rotoxicity is dose dependent [32, 33, 43]. We cannot exclude
that other factors also played a role in renal impairment.
One issue we explored in detail was the potential effect of
rifampicin MIC on combination treatment outcome. Acb
resistance to rifampicin may involve different mechanisms. As
recently observed [34], low to intermediate resistance (MICs
4–16 mg/L) appears to be mostly related to altered bacterial
membrane permeability, whereas mutations in the rpoB gene
are associated with high-level resistance (MICs >16 mg/L). Ac-
cordingly, and also in agreement with the French Society of
Microbiology [36], we used a breakpoint of >16 to deﬁne resis-
tance. Theoretically, because colistin impairs bacterial mem-
brane permeability, synergy should be expected mostly in cases
due to strains with altered membrane permeability to rifampi-
cin [34]. However, even in the subgroup of patients with
MIC≤ 16, no difference for the primary outcome was observed
with combination treatment. As shown by both the interaction
analysis and the multivariable analyses (Figure 2, Table 3), ri-
fampicin MIC did not inﬂuence the efﬁcacy of combination
treatment.
The addition of rifampicin to colistin led to a higher rate of
hepatic toxicity. The overall rate of adverse events directly at-
tributable to either colistin or rifampicin was in line with previ-
ous ﬁndings [32, 33, 43], and there were few serious adverse
events and no drug-related deaths.
The observed mortality rate was lower than that considered
when the trial was planned (43% rather than 60%). The expect-
ed mortality of 60% in the control arm was based on our previ-
ous clinical data [37]. Nonetheless, if we assumed a control arm
mortality rate of 47% (ie, the mean value reported by a recent
review) [44], 175 subjects would be needed to detect the same
effect. A potential limitation of this trial was the lack of blind-
ing. However, the pragmatic design and the hard primary
outcome made blinding not essential.
In conclusion, rifampicin addition to colistin did not
improve survival in serious infections due to XDR Acb. The
clinical implication of this ﬁnding is that rifampicin should not
be added to colistin in clinical practice, at least on a routine
basis. The major issue related to Acb treatment remains the
current shortage of efﬁcacy data from comparative studies. At-
tempts have been made to improve colistin efﬁcacy by unortho-
dox antimicrobial combinations, but none of these proved
superiority over colistin monotherapy [14]. As the clinical de-
velopment of novel antimicrobial agents progresses slowly, any
effort should be made to optimize the use of already available
drugs. This should only be pursued, however, through ade-
quately powered, randomized clinical trials.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The posted
materials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Table 4. Safety Outcomes
Outcome
Colistin + Rifampicin
Arm (n = 101)
Colistin Arm
(n = 101)
P
Valuea
Renal dysfunctionb 24 (23.7) 29 (28.7) .52
Risk 8 (33.3) 13 (44.8)
Injury 6 (25) 8 (27.6)
Failure 9 (37.5) 8 (27.6)
Loss 1 (4.2) 0
End-stage kidney
disease
0 0
Colistin dose
reduction/
discontinuation
8 (33)/9 (37) 6 (21)/9 (31)
Hepatic dysfunction 21 (20.8) 12 (11.9) .13
Rifampicin dose
reduction/
discontinuation
2 (9)/10 (48) . . .
Neurotoxicity 1 (0.99) 0 >.99
Colistin dose
reduction/
discontinuation
0/1 (100) . . .
Rifampicin dose
reduction/
discontinuation
0/1 (100) . . .
Data are presented as No. (%).
a Exact χ2 test.
b Graded according to the RIFLE criteria: risk, injury, failure, loss, end-stage
kidney disease [32, 33].
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